Navigation Links
InspireMD's MGuard Stent Shows Lower Mortality Rate in STEMI Patients at Twelve Months Compared to Control Group
Date:10/29/2013

reliance on subcontractors for assistance, (vii) insufficient or inadequate reimbursement by governmental and other third party payers for our products, (viii) our efforts to successfully obtain and maintain intellectual property protection covering our products, which may not be successful, (ix) legislative or regulatory reform of the healthcare system in both the U.S. and foreign jurisdictions, (x) our reliance on single suppliers for certain product components, (xi) the fact that we will need to raise additional capital to meet our business requirements in the future and that such capital raising may be costly, dilutive or difficult to obtain and (xii) the fact that we conduct business in multiple foreign jurisdictions, exposing us to foreign currency exchange rate fluctuations, logistical and communications challenges, burdens and costs of compliance with foreign laws and political and economic instability in each jurisdiction. More detailed information about the Company and the risk factors that may affect the realization of forward looking statements is set forth in the Company's filings with the Securities and Exchange Commission (SEC), including the Company's Annual Report on Form 10-K and its Quarterly Reports on Form 10-Q. Investors and security holders are urged to read these documents free of charge on the SEC's web site at http://www.sec.gov. The Company assumes no obligation to publicly update or revise its forward-looking statements as a result of new information, future events or otherwise.

Investor Contacts:
Todd Fromer / Garth Russell
KCSA Strategic Communications
Phone: 212-896-1215 / 212-896-1250
Email: tfromer@kcsa.com / grussell@kcsa.com

Media Contacts:
Lewis Goldberg / Samantha Wolf'/>"/>

SOURCE InspireMD
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related medicine technology :

1. InspireMDs MGuard Embolic Protection Stent (EPS) Shows Lower Mortality Rate in STEMI Patients at Six Months Compared to Control Group
2. InspireMD to Discuss MGuard(TM) and the MASTER Randomized Trial Results at the ICI 2012 Meeting
3. InspireMD Announces Positive Results From MGuard(TM) Stent MASTER Trial for Emergency Treatment of Heart Attack Patients
4. Kimberly-Clark Health Care Receives FDA Clearance For KIMGUARD ONE-STEP Sterilization Wrap Portfolio With One-Year Maintenance Of Package Integrity And Amsco V-PRO maX (Flexible Cycle)
5. MiStent SES demuestra ser único en el entorno clínico
6. MiStent SES erweist sich im klinischen Umfeld als einzigartig
7. Pediatric Group Offers Consistent Vision Care Across Its Network with Spot Vision Screener
8. MiStent SES Shown to be Unique in Clinical Setting
9. Micell Technologies Announces Development and Distribution Agreement to Bring MiStent SES to China
10. Mylan Supports Generic Drug Industrys Call on FDA to Uphold Consistent, Proven International Standard for Biosimilar Naming
11. Freudenberg-NOK Sealing Technologies Announces Screw Connections Based on Hygienic Design Consistently Achievable
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/31/2015)... Aug. 31, 2015 The Wolf Administration today ... Pennsylvania State Police and local ... naloxone. Heroin and opioid overdose are the ... , killing more individuals than those involved in ... died from a drug overdose. " ...
(Date:8/31/2015)... 2015  The departments of Drug and Alcohol Programs ... Concept 90 to raise awareness for International Overdose Awareness ... Pennsylvania and help more Pennsylvanians with ... through the Building Bridges to Recovery initiative. ... day to a disease that is fully treatable, if ...
(Date:8/31/2015)... -- Dipexium Pharmaceuticals, Inc. (NASDAQ: DPRX ), a late-stage ... Locilex® (pexiganan cream 0.8%), a novel, broad spectrum, topical ... investor conferences in September. , ... LLC Emerging Growth Conference in New ... President & Chief Executive Officer, will present a corporate ...
Breaking Medicine Technology:Departments of Drug & Alcohol Programs and Health Announce Report 289 Pennsylvanian Lives Saved by Naloxone 2Departments of Drug & Alcohol Programs and Health Announce Report 289 Pennsylvanian Lives Saved by Naloxone 3Pennsylvania Departments of Drug & Alcohol Programs and Health Kick-off Second Annual Building Bridges to Recovery Initiative 2Dipexium Pharmaceuticals Announces Participation in Four Investor Conferences in September 2Dipexium Pharmaceuticals Announces Participation in Four Investor Conferences in September 3
... First-in-Class Biologic Treatment Option Now Available for ... Use in Pediatric Patients with JIA(1,2) -, PRINCETON, ... ) today announced that the U.S. Food and Drug,Administration (FDA) ... patients six years and older with moderately to,severely active polyarticular ...
... Model Created Using Piecewise Smooth Subdivision Surface Provides Both ... of Fallot Patients, SEATTLE, April 8, 2008 ... and volumetric insights,that help cardiologists diagnose and treat patients ... in the American Journal,Cardiology (2008; Vol. 101, Issue 1, ...
Cached Medicine Technology:U.S. Food and Drug Administration Approves ORENCIA(R) (abatacept) for the Treatment of Moderate-to-Severe Polyarticular Juvenile Idiopathic Arthritis (JIA) in Patients Six Years and Older 2U.S. Food and Drug Administration Approves ORENCIA(R) (abatacept) for the Treatment of Moderate-to-Severe Polyarticular Juvenile Idiopathic Arthritis (JIA) in Patients Six Years and Older 3U.S. Food and Drug Administration Approves ORENCIA(R) (abatacept) for the Treatment of Moderate-to-Severe Polyarticular Juvenile Idiopathic Arthritis (JIA) in Patients Six Years and Older 4U.S. Food and Drug Administration Approves ORENCIA(R) (abatacept) for the Treatment of Moderate-to-Severe Polyarticular Juvenile Idiopathic Arthritis (JIA) in Patients Six Years and Older 5U.S. Food and Drug Administration Approves ORENCIA(R) (abatacept) for the Treatment of Moderate-to-Severe Polyarticular Juvenile Idiopathic Arthritis (JIA) in Patients Six Years and Older 6U.S. Food and Drug Administration Approves ORENCIA(R) (abatacept) for the Treatment of Moderate-to-Severe Polyarticular Juvenile Idiopathic Arthritis (JIA) in Patients Six Years and Older 7U.S. Food and Drug Administration Approves ORENCIA(R) (abatacept) for the Treatment of Moderate-to-Severe Polyarticular Juvenile Idiopathic Arthritis (JIA) in Patients Six Years and Older 8U.S. Food and Drug Administration Approves ORENCIA(R) (abatacept) for the Treatment of Moderate-to-Severe Polyarticular Juvenile Idiopathic Arthritis (JIA) in Patients Six Years and Older 9U.S. Food and Drug Administration Approves ORENCIA(R) (abatacept) for the Treatment of Moderate-to-Severe Polyarticular Juvenile Idiopathic Arthritis (JIA) in Patients Six Years and Older 10Three Dimensional Visualization of Right Ventricle Provides Important Information for Treatment of Patients with Tetralogy of Fallot, According to a Study in The American Journal of Cardiology 2Three Dimensional Visualization of Right Ventricle Provides Important Information for Treatment of Patients with Tetralogy of Fallot, According to a Study in The American Journal of Cardiology 3
(Date:9/1/2015)... ... September 01, 2015 , ... ... Nurse Scholar-in Residence at the Institute of Medicine (IOM) of the National Academies. ... at Columbia University School of Nursing. A member of the Institute of Medicine ...
(Date:9/1/2015)... ... 01, 2015 , ... Ogawa’s new massage chairs tout innovative functionality that change ... than ever before. With the goal of bringing wellness to the world, Ogawa introduces ... , As in its name, the Ogawa Refresh aims to “refresh” ...
(Date:9/1/2015)... Aventura, Florida (PRWEB) , ... September 01, 2015 ... ... across language barriers and international borders seldom arise at the most convenient time ... which is always ready to help. , Universal Translation Services has ...
(Date:9/1/2015)... ... 01, 2015 , ... Dr. Trace Curry successfully placed one of the first ... last month the FDA has approved two intra-gastric balloons, the ORBERA ™ Managed ... first incisionless, reversible, weight loss procedures available to Americans. , Dr. Curry, ...
(Date:9/1/2015)... (PRWEB) , ... September 01, 2015 , ... ... to send information about new patients directly from Practice Perfect to FOTO enabling ... data entry. , Steven Presement, President of Practice Perfect, stated ...
Breaking Medicine News(10 mins):Health News:Columbia Nursing’s Suzanne Bakken Named Distinguished Institute of Medicine Nurse Scholar-in-Residence 2Health News:Ogawa World USA Releases New Massage Chairs to the US 2Health News:Ogawa World USA Releases New Massage Chairs to the US 3Health News:Universal Translation Services Provides Quality Translations 24 Hours a Day Including Weekends 2Health News:Universal Translation Services Provides Quality Translations 24 Hours a Day Including Weekends 3Health News:Dr. Trace Curry Performs First ORBERA™ Intra-gastric Balloon in Ohio at JourneyLite, a New Incisionless Option For The Treatment of Obesity 2Health News:FOTO Announces New Integration Partnership with Practice Perfect 2
... volunteers for HIV/AIDS research in the United States and ... that the forms were extremely long and used wording ... understanding, according to bioethicists at The Johns Hopkins University. ... U.S. government-sponsored, multinational HIV/AIDS research conducted in 2006 revealed ...
... THURSDAY, July 14 (HealthDay News) -- A novel version ... and animals has managed to jump from one species and ... virus is from the adenovirus family, responsible for the common ... now -- unlike other types of viruses -- these particular ...
... July 14, 2011) In a study, Identification of ... in the July 2011 issue of the Journal ... of Dental Medicine found that dental visits represented a ... individuals with diabetes or pre-diabetes who are unaware of ...
... , THURSDAY, July 14 (HealthDay News) -- Military veterans who ... suicide attempt, but have an overall heightened risk of death ... study, published online in BioMed Central Public Health , ... seen at a Veterans Affairs medical center for a suicide ...
... Reporter , WEDNESDAY, July 13 (HealthDay News) -- Top ... air traffic controllers napping on the job are missing ... Studies have shown that short "power naps" have ... for people impaired by drowsiness, said Dr. Alon Avidan, ...
... cost-effective for treating people who are severely obese, but also ... study from Washington University School of Medicine in St. Louis. ... people, the researchers say. Patients who have the surgery ... have fewer medical problems related to their weight, indicating the ...
Cached Medicine News:Health News:Informed-consent forms should be shortened, simplified, Johns Hopkins bioethicists confirm 2Health News:Informed-consent forms should be shortened, simplified, Johns Hopkins bioethicists confirm 3Health News:Novel Virus 'Jumped' From Monkeys to Humans, Researchers Find 2Health News:Novel Virus 'Jumped' From Monkeys to Humans, Researchers Find 3Health News:Novel Virus 'Jumped' From Monkeys to Humans, Researchers Find 4Health News:Dentists can identify people with undiagnosed diabetes, Columbia researchers show 2Health News:Sometimes Sleeping on the Job May Be a Good Thing 2Health News:Sometimes Sleeping on the Job May Be a Good Thing 3Health News:Weight-loss surgery cost-effective for all obese 2Health News:Weight-loss surgery cost-effective for all obese 3
Complete Blink-N-Clean lens drops cleans and clears lenses in a blink. It is a unique blend of gentle to the eye ingredients that conveniently cleans, clears and keeps lenses feeling comfortable thro...
... preservative free lubricating and rewetting ... eyes while you're wearing soft ... free formula is ideal for ... to preservatives and for frequent ...
Saline Solution to rinse and store soft contact lenses and for heat disinfection....
Sensitive Eyes Plus Saline Solution to rinse soft contact lenses The unique, gentle, pH-balanced formula contains potassium, an ingredient found in tears....
Medicine Products: